Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Beachler

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2010
Kaposi sarcoma-associated herpesvirus serum DNA and antibodies not associated with subsequent non-Hodgkin lymphoma riskDaniel C Beachler, Lan L Gellert, Lisa P Jacobson, et al.
Papillomavirus Research (Amsterdam, Netherlands)|February 28, 2017
HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infectionDaniel C Beachler, Tim Waterboer, Christine M Pierce Campbell, et al.
Diabetes, Obesity & Metabolism|January 18, 2024
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohortsCristina Rebordosa, Reimar W Thomsen, Arlene K Tave, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 3, 2011
Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adultsDaniel C Beachler, Kathleen M Weber, Joseph B Margolick, et al.
Sexually Transmitted Diseases|January 14, 2015
A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infectionDaniel C Beachler, Raphael Viscidi, Elizabeth A Sugar, et al.
Oral Oncology|October 11, 2014
Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individualsDaniel C Beachler, Alison G Abraham, Michael J Silverberg, et al.
Drug Safety|December 17, 2022
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingCatherine B Johannes, Daniel C Beachler, J Bradley Layton, et al.
Drug Safety|December 30, 2022
Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingHeather E Danysh, Catherine B Johannes, Daniel C Beachler, et al.
Journal of the National Cancer Institute|October 16, 2015
Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV InfectionDaniel C Beachler, Aimée R Kreimer, Mark Schiffman, et al.
American Journal of Epidemiology|December 7, 2014
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adultsDaniel C Beachler, Elizabeth A Sugar, Joseph B Margolick, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2010
Kaposi sarcoma-associated herpesvirus serum DNA and antibodies not associated with subsequent non-Hodgkin lymphoma riskDaniel C Beachler, Lan L Gellert, Lisa P Jacobson, et al.
Papillomavirus Research (Amsterdam, Netherlands)|February 28, 2017
HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infectionDaniel C Beachler, Tim Waterboer, Christine M Pierce Campbell, et al.
Diabetes, Obesity & Metabolism|January 18, 2024
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohortsCristina Rebordosa, Reimar W Thomsen, Arlene K Tave, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 3, 2011
Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adultsDaniel C Beachler, Kathleen M Weber, Joseph B Margolick, et al.
Sexually Transmitted Diseases|January 14, 2015
A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infectionDaniel C Beachler, Raphael Viscidi, Elizabeth A Sugar, et al.
Oral Oncology|October 11, 2014
Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individualsDaniel C Beachler, Alison G Abraham, Michael J Silverberg, et al.
Drug Safety|December 17, 2022
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingCatherine B Johannes, Daniel C Beachler, J Bradley Layton, et al.
Drug Safety|December 30, 2022
Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingHeather E Danysh, Catherine B Johannes, Daniel C Beachler, et al.
Journal of the National Cancer Institute|October 16, 2015
Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV InfectionDaniel C Beachler, Aimée R Kreimer, Mark Schiffman, et al.
American Journal of Epidemiology|December 7, 2014
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adultsDaniel C Beachler, Elizabeth A Sugar, Joseph B Margolick, et al.
Pageof 6